Category Patents/Designs/Trade Secrets

Concerns Continue Over Generic Drug Seizures As Legality Debates Begin

Developing nations led by Brazil and India, along with public health providers and advocates, this week continue to press strong concern over seizures of legitimate shipments of generic pharmaceuticals destined for poor patients in the developing world. Raising the issue at the World Trade Organization again, they say new research into numerous shipments of legitimate drugs delayed by authorities in the Netherlands have elevated doubts and may mean potentially thousands of patients put at risk.

US Patent Reform Bills And Jobs: Critical Timing, Critical Differences

The United States patent reform bills offered up Tuesday fall well short of what is needed to protect innovation and intellectual property rights, say myriad small tech companies, large-cap manufacturers, pharmaceutical firms and inventors. In fact, they say, it even threatens jobs at a time when the economy is in desperate need of them.

But proponents argue that it is precisely the type of measure needed to promote jobs, reduce lawsuits and poor patent quality that put a drag on innovation and the economy.

In Biotech Industry, Cash Flow Fears And Patent Questions

Patent reform, universal health care, and intellectual property rights protection of new health and environmental technologies are critical not only for the biotechnology industry but for improvements in public health, the president of the Biotechnology Industry Organization (BIO) said Thursday.

Innovation Policy: The Balance Between Standards and Patent Regulation

greveBy Georg Greve

Interconnectivity, commoditisation and increased reuse and recombination are key trends within the maturing information and communication technologies (ICT) industry that drive innovation and development. Harnessing the innovative and economic potential of the ICT sector depends on a variety of factors, including open innovation models, such as free software.

Drug Patent Linkage Is Subject Of Court Case, Dispute In India

Should national drug control bodies grant marketing licences to generic medicine companies only if their products do not possibly infringe existing patent rights? Yes, German pharmaceutical company Bayer told the High Court of Delhi last week when the court heard arguments in an ongoing court case on patent linkage.

Enforcement, Creative R&D Financing Priority Issues For Public Health in 2009

The number and intensity of debates over the role of intellectual property rights in public health is set to increase in 2009.

New leadership and new mandates for key intergovernmental organisations implemented last year have created opportunity for change. And while old debates over the balance between IP rights and access to health products are not going away, this year will see more exploration at the intergovernmental level of different systems to stimulate innovation.

Industry Pushes For Biosimilars Approval Process; Some IGOs Take Notice

Key players in the biotechnology industry are leading an effort to obtain global approval processes for generic biological medicines, which experts say could provide cheaper access to costly but widely prescribed and promising treatments.

欧盟有关知识产权的强硬规定被视为对贫困国家医药获得的威胁

布鲁塞尔 - 全球公共卫生活跃分子声称，欧盟执意要在一系列自由贸易协议中添加有关医药专利的强硬规定将会妨害发展中国家获得医药。

لأحكام التجارية القوية للاتحاد الأوروبي حول الملكية الفكرية تعتبر تهديدا على نفاذ البلدان الفقيرة إلى الأدوية

ابروكسل- إن الجهود التي يبذلها الاتحاد الأوروبي لإدراج أحكام حول براءات المستحضرات الصيدلانية في سلسلة من اتفاقات التجارة الحرة التي يتفاوض حولها قد تشكل تهديدا على إمكانية الحصول على الأدوية في البلدان النامية، على حد قول الناشطين في مجال الصحة العامة على الصعيد العالمي.

Des dispositions renforçant la propriété intellectuelle dans certains accords de l’UE menacent l’accès aux médicaments dans les pays pauvres

BRUXELLES - Selon certains activistes de la santé publique mondiale, les efforts de l’Union européenne (UE) pour intégrer des dispositions sur les brevets pharmaceutiques dans un certain nombre d’accords de libre échange en cours de négociation pourraient mettre en péril l’accès aux médicaments dans les pays en développement.